BigHat Biosciences

Biotech · Artificial Intelligence · Therapeutics

Funding

BigHat Biosciences lands $75M Series C for AI-designed cancer drugs

Having already dosed a patient with its lead AI-designed antibody, the startup now must prove the biology works in humans, not just the algorithm.

• BigHat Biosciences closed a $75 million Series C co-led by DFJ Growth and Premji Invest, bringing its total funding raised to date to $223 million.
• The clinical-stage biotech pairs AI protein design with automated wet-lab experimentation, generating its own proprietary biological data rather than relying on public datasets.
• Proceeds will advance BigHat's pipeline, including BHB810, a CDH17-targeted antibody-drug conjugate for gastric cancer already in Phase 1, and BHB299 toward the clinic.
• BHB299, a second internally developed oncology program, is expected to enter human testing in 2027.
• The syndicate includes the venture arms of Amgen, Eli Lilly and Merck alongside Andreessen Horowitz, signaling pharma-strategic as well as financial conviction in the platform.
• The $75 million Series C is the same size as BigHat's 2022 Series B, a four-year gap that points to steady rather than compounding capital inflow.
• As AI drug-discovery platforms increasingly face this test, having an internally designed biologic already dosing patients, rather than only design partnerships, sets BigHat apart in a still-unproven field.